GCLabs

Search for Test Items

EDN (eosinophil derived neurotoxin)

GC Labs code	Q620	Test Field	Immunology
Compulsory forms

GC Labs code

Q620

Test Field

Immunology

Compulsory forms

Information

Test method	ELISA (Enzyme linked immunosorbent assay)
Specimen (mL)	S 1.0
Specimen storage	Frozen
Specimen stability	Refrigerated (2 days)
Test schedule	Wed
Analytical time (day)	1

Test method

ELISA (Enzyme linked immunosorbent assay)

Specimen (mL)

S 1.0

Specimen storage

Frozen

Specimen stability

Refrigerated (2 days)

Test schedule

Wed

Analytical time (day)

Reference range/Unit	[Serum] ≤ 44.24 (ng/mL)
Clinical Significance	Eosinophil-Derived Neurotoxin (EDN) is a protein released during eosinophil degranulation and serves as an indirect marker of eosinophil activation. EDN can be quantitatively measured in serum samples, and it has been reported to be potentially useful in clinical evaluation of asthma. In particular, EDN may be useful as a supplementary diagnostic aid for asthma in pediatric patients where pulmonary function testing is difficult to perform. It has also been reported as a potential biomarker for predicting response and monitoring efficacy in patients undergoing therapy. However, EDN levels may be elevated in a variety of eosinophil-associated disorders, and thus its use as a sole diagnostic marker for any specific condition is limited. Interpretation of test results should always be made in the context of clinical presentation and in conjunction with other laboratory and diagnostic findings.
Remark

Reference range/Unit

 [Serum]
≤ 44.24 (ng/mL)

Clinical Significance

Eosinophil-Derived Neurotoxin (EDN) is a protein released during eosinophil degranulation and serves as an indirect marker of eosinophil activation. EDN can be quantitatively measured in serum samples, and it has been reported to be potentially useful in clinical evaluation of asthma. In particular, EDN may be useful as a supplementary diagnostic aid for asthma in pediatric patients where pulmonary function testing is difficult to perform. It has also been reported as a potential biomarker for predicting response and monitoring efficacy in patients undergoing therapy. However, EDN levels may be elevated in a variety of eosinophil-associated disorders, and thus its use as a sole diagnostic marker for any specific condition is limited. Interpretation of test results should always be made in the context of clinical presentation and in conjunction with other laboratory and diagnostic findings.

Remark